Bronwyn E. Brown

发表

Molecular Alterations in a Mouse Cardiac Model of Friedreich Ataxia: An Impaired Nrf2 Response Mediated via Upregulation of Keap1 and Activation of the Gsk3β Axis.

D. Richardson, C. Hawkins, B. E. Brown, 2017, The American journal of pathology.

Advanced Glycation End Products Acutely Impair Ca2+ Signaling in Bovine Aortic Endothelial Cells

A. Jenkins, A. Januszewski, M. Hill, 2013, Front. Physiol..

Role of hypochlorous acid (HOCl) and other inflammatory mediators in the induction of macrophage extracellular trap formation

B. Rayner, C. Hawkins, Yunjia Zhang, 2018, Free radical biology & medicine.

Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles.

R. Dean, M. Davies, B. E. Brown, 2003, European journal of biochemistry.

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease

P. Angus, J. Furness, J. Forbes, 2016, World journal of gastroenterology.

The Roles of Protein Glycation, Glycoxidation, and Advanced Glycation End-Product Formation in Diabetes-Induced Atherosclerosis

M. Davies, B. E. Brown, D. M. Reyk, 2006 .

The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase

P. Barter, A. Jenkins, K. Rye, 2007, Diabetologia.

Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I

P. Barter, A. Jenkins, G. Dusting, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).

K. Rye, M. Davies, C. Hawkins, 2013, The Biochemical journal.

Supplementation with carnosine decreases plasma triglycerides and modulates atherosclerotic plaque composition in diabetic apo E(-/-) mice.

Christine H. J. Kim, F. Torpy, M. Davies, 2014, Atherosclerosis.

Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I

P. Barter, K. Rye, M. Davies, 2008, Diabetologia.

Role of Myeloperoxidase Oxidants in the Modulation of Cellular Lysosomal Enzyme Function: A Contributing Factor to Macrophage Dysfunction in Atherosclerosis?

Tessa J. Barrett, M. Davies, C. Hawkins, 2016, PloS one.

Glycation of low‐density lipoprotein results in the time‐dependent accumulation of cholesteryl esters and apolipoprotein B‐100 protein in primary human monocyte‐derived macrophages

M. Davies, B. E. Brown, D. van Reyk, 2007, The FEBS journal.

Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins

M. Davies, B. E. Brown, N. Cook, 2006, Diabetologia.

Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells

R. Dean, M. Davies, B. E. Brown, 2005, Diabetologia.

Comparative reactivity of the myeloperoxidase-derived oxidants HOCl and HOSCN with low-density lipoprotein (LDL): Implications for foam cell formation in atherosclerosis.

K. Croft, M. Davies, C. Hawkins, 2015, Archives of biochemistry and biophysics.

Effect of Exposure of Human Monocyte-Derived Macrophages to High, versus Normal, Glucose on Subsequent Lipid Accumulation from Glycated and Acetylated Low-Density Lipoproteins

M. Davies, B. E. Brown, D. van Reyk, 2011, Experimental diabetes research.